Monitor the June 10 annual meeting outcome for stockholder approval of board reconstitution. The delayed appointment of Dr. Vousden is a minor scheduling change with no immediate trading implications.
Price Chart
Executive Summary
Sensei Biotherapeutics filed a DEFA14A supplement to its definitive proxy statement, updating board reconstitution plans contingent on stockholder approval at the June 10, 2026 annual meeting. Director nominee Karen Vousden, Ph.D. has delayed her appointment to later in 2026 for personal reasons, and the board has approved a five-director size effective June 12, 2026, with Bob Holmen as chair of the Nominating and Corporate Governance Committee. This is a routine administrative update with no material financial impact.
Key Financial Metrics
Key Facts
- Annual meeting scheduled for June 10, 2026, with record date April 13, 2026.
- Director nominee Karen Vousden, Ph.D. delayed appointment to Q3/Q4 2026 due to personal reasons.
- Board size set at five directors effective June 12, 2026, pending stockholder approval.
- Bob Holmen to chair Nominating and Corporate Governance Committee effective June 12, 2026.
- Board recommendation on all proposals remains unchanged from the April 27, 2026 definitive proxy statement.
Financial Impact
No financial figures disclosed; administrative proxy supplement only.
Risk Factors
- Stockholder approval of Required Company Stockholder Matters is not guaranteed.
- Further delays or changes in board composition could occur.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-236834 |
| Document: 0001193125-26-236834-index-headers.html | 0001193125-26-236834 |
| Document: 0001193125-26-236834-index.html | 0001193125-26-236834 |
| Document: 0001193125-26-236834.txt | 0001193125-26-236834 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 16, 2026 19w ago | 3 | $13.86 | awaiting T+5 | — | — |
Jun 15, 2026 19w ago | 8-K | $13.04 | awaiting T+5 | — | — |
Jun 15, 2026 19w ago | EFFECT | $13.04 | awaiting T+5 | — | — |
Jun 10, 2026 19w ago | S-3/A | $10.79 $13.85 | ▲ +28.36% | ▲ +27.93% | — |
Jun 10, 2026 19w ago | 8-K | $10.79 $13.85 | ▲ +28.36% | ▲ +27.93% | — |
Jun 2, 2026 21w ago | 10-K/A | $16.10 $12.63 | ▼ −21.53% | ▼ −18.56% | — |
Jun 2, 2026 21w ago | S-3/A | $16.10 $12.63 | ▲ +21.53% | ▲ +18.56% | — |
Jun 1, 2026 21w ago | Insider Cluster | $16.10 $12.63 | ▲ +21.53% | ▲ +18.56% | — |
May 22, 2026 22w ago | DEFA14A | $16.47 $19.79 | ▲ +20.16% | ▲ +19.07% | — |
May 22, 2026 22w ago | 8-K | $16.47 $19.79 | ▲ +20.16% | ▲ +19.07% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers